Gene-expression profiling in vaccine therapy and immunotherapy for cancer

Davide Bedognetti, Ena Wang, Mario Roberto Sertoli, Francesco M. Marincola

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

The identification of tumor antigens recognized by T cells led to the design of therapeutic strategies aimed at eliciting adaptive immune responses. The last decade of experience has shown that, although active immunization can induce enhancement of anticancer T-cell precursors (easily detectable in standard assays), most often they are unable to induce tumor regression and, consequently, have scarcely any impact on overall survival. Moreover, in the few occasions when tumor rejection occurs, the mechanisms determining this phenomenon remain poorly understood, and data derived from in vivo human observations are rare. The advent of high-throughput gene-expression analysis (microarrays) has cast new light on unrecognized mechanisms that are now deemed to be central for the development of efficient immune-mediated tumor rejection. The aim of this article is to review the data on the molecular signature associated with this process. We believe that the description of how the mechanism of immune-mediated tissue destruction occurs would contribute to our understanding of why it happens, thereby allowing us to develop more effective immune therapeutic strategies.

Original languageEnglish
Pages (from-to)555-565
Number of pages11
JournalExpert Review of Vaccines
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 2010
Externally publishedYes

Fingerprint

Active Immunotherapy
Gene Expression Profiling
Immunotherapy
T-Lymphoid Precursor Cells
Neoplasms
Adaptive Immunity
Neoplasm Antigens
Microarray Analysis
Vaccination
T-Lymphocytes
Gene Expression
Survival
Therapeutics

Keywords

  • Cancer immunotherapy
  • Gene expression
  • Immunologic constant
  • Melanoma
  • Microarray
  • Tumor rejection
  • Vaccine therapy

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Gene-expression profiling in vaccine therapy and immunotherapy for cancer. / Bedognetti, Davide; Wang, Ena; Sertoli, Mario Roberto; Marincola, Francesco M.

In: Expert Review of Vaccines, Vol. 9, No. 6, 06.2010, p. 555-565.

Research output: Contribution to journalReview article

Bedognetti, Davide ; Wang, Ena ; Sertoli, Mario Roberto ; Marincola, Francesco M. / Gene-expression profiling in vaccine therapy and immunotherapy for cancer. In: Expert Review of Vaccines. 2010 ; Vol. 9, No. 6. pp. 555-565.
@article{b635aed4f202493880f5658f6317b418,
title = "Gene-expression profiling in vaccine therapy and immunotherapy for cancer",
abstract = "The identification of tumor antigens recognized by T cells led to the design of therapeutic strategies aimed at eliciting adaptive immune responses. The last decade of experience has shown that, although active immunization can induce enhancement of anticancer T-cell precursors (easily detectable in standard assays), most often they are unable to induce tumor regression and, consequently, have scarcely any impact on overall survival. Moreover, in the few occasions when tumor rejection occurs, the mechanisms determining this phenomenon remain poorly understood, and data derived from in vivo human observations are rare. The advent of high-throughput gene-expression analysis (microarrays) has cast new light on unrecognized mechanisms that are now deemed to be central for the development of efficient immune-mediated tumor rejection. The aim of this article is to review the data on the molecular signature associated with this process. We believe that the description of how the mechanism of immune-mediated tissue destruction occurs would contribute to our understanding of why it happens, thereby allowing us to develop more effective immune therapeutic strategies.",
keywords = "Cancer immunotherapy, Gene expression, Immunologic constant, Melanoma, Microarray, Tumor rejection, Vaccine therapy",
author = "Davide Bedognetti and Ena Wang and Sertoli, {Mario Roberto} and Marincola, {Francesco M.}",
year = "2010",
month = "6",
doi = "10.1586/erv.10.55",
language = "English",
volume = "9",
pages = "555--565",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Gene-expression profiling in vaccine therapy and immunotherapy for cancer

AU - Bedognetti, Davide

AU - Wang, Ena

AU - Sertoli, Mario Roberto

AU - Marincola, Francesco M.

PY - 2010/6

Y1 - 2010/6

N2 - The identification of tumor antigens recognized by T cells led to the design of therapeutic strategies aimed at eliciting adaptive immune responses. The last decade of experience has shown that, although active immunization can induce enhancement of anticancer T-cell precursors (easily detectable in standard assays), most often they are unable to induce tumor regression and, consequently, have scarcely any impact on overall survival. Moreover, in the few occasions when tumor rejection occurs, the mechanisms determining this phenomenon remain poorly understood, and data derived from in vivo human observations are rare. The advent of high-throughput gene-expression analysis (microarrays) has cast new light on unrecognized mechanisms that are now deemed to be central for the development of efficient immune-mediated tumor rejection. The aim of this article is to review the data on the molecular signature associated with this process. We believe that the description of how the mechanism of immune-mediated tissue destruction occurs would contribute to our understanding of why it happens, thereby allowing us to develop more effective immune therapeutic strategies.

AB - The identification of tumor antigens recognized by T cells led to the design of therapeutic strategies aimed at eliciting adaptive immune responses. The last decade of experience has shown that, although active immunization can induce enhancement of anticancer T-cell precursors (easily detectable in standard assays), most often they are unable to induce tumor regression and, consequently, have scarcely any impact on overall survival. Moreover, in the few occasions when tumor rejection occurs, the mechanisms determining this phenomenon remain poorly understood, and data derived from in vivo human observations are rare. The advent of high-throughput gene-expression analysis (microarrays) has cast new light on unrecognized mechanisms that are now deemed to be central for the development of efficient immune-mediated tumor rejection. The aim of this article is to review the data on the molecular signature associated with this process. We believe that the description of how the mechanism of immune-mediated tissue destruction occurs would contribute to our understanding of why it happens, thereby allowing us to develop more effective immune therapeutic strategies.

KW - Cancer immunotherapy

KW - Gene expression

KW - Immunologic constant

KW - Melanoma

KW - Microarray

KW - Tumor rejection

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=77953233668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953233668&partnerID=8YFLogxK

U2 - 10.1586/erv.10.55

DO - 10.1586/erv.10.55

M3 - Review article

C2 - 20518712

AN - SCOPUS:77953233668

VL - 9

SP - 555

EP - 565

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -